Figure 4.

Rolipram inhibits Rho activation. Cultures were cut and treated with 50 nM rolipram for 6 days prior to immunolabelling with phalloidin (green) and anti-phosphomyosin (red; A–C). Quantification was performed by measuring the intensities of each antibody staining, normalized to the number of DAPI-nuclei, and compared with the effects of Rho/ROCK inhibitors C3 (1 μg mL⁻¹) and Y27632 (1 μM; D). Scale bar 25 μm. *P < 0.05, **P < 0.01, ***P < 0.001; significant differences between control and cut, and treatments and cut. Western blotting for activated RhoA using beads and total Rho was performed on these cell lysates (E). The blots shown are representative of experiments performed three times.